| Source: | Streptomyces alboniger |
| Synonyms | Stylomycin, P638, Puromycin |
| Description: | Puromycin is a protein synthesis inhibitor. It causes premature chain termination |
| CAS number: | 58-58-2 |
| Merck index: | 12, 8130 |
| Molecular weight: | 471.52 |
| Structure: | 
 |
| Molecular Formula: | C22H29N7O5.2HCl.2H2 |
Solubility
information: | |
| Specifications | |
| Appearance: | White powder |
| Purity | At least 98% by TLC, HPLC |
| λmax: | 275, 267 |
| Melting point | 168°C-178°C |
| Solubility | Clear colorless solution at 50mg/ml of water |
| Storage | +4°C. |
| Applications | Puromycin is an antibiotic used for selecting mammalian cell lines, which have been transformed by vectors that express puromycin-N-acetyl-transferase
Puromycin is also a Antineoplastic agent.
Puromycin possesses antoprotozoal activities (against Trypanozoma) |
| Warnings | TOXIC. POTENTIAL CARCINOGEN |
| Classification | Nucleoside antibiotic
Protein synthesis inhibitor |
| Related products | Puromycin Aminonucleoside |
| | For Research use only. Not for Human or Drug use
GMP/API grade
No genetically modified organisms are used.Raw materials from animal origin info
|
| Publications | |
| | Karsten SL, Sang TK, Gehman LT, Chatterjee S, Liu J, Lawless GM, Sengupta S, Berry RW, Pomakian J, Oh HS, Schulz C, Hui KS, Wiedau-Pazos M, Vinters HV, Binder LI, Geschwind DH, Jackson GR.
A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration.
Neuron. 2006 Sep 7;51(5):549-60 |
| | Abe M, Sato Y.
Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) is required for the development of vascular as well as hematopoietic system in embryoid bodies.
Genes Cells. 2006 Jul;11(7):719-29. |
| | Iwaki T, Castellino FJ.
A single plasmid transfection that offers a significant advantage associated with puromycin selection in Drosophila Schneider S2 cells expressing heterologous proteins.
Cytotechnology. 2008 May;57(1):45-9. |
| | Croons V, Martinet W, Herman AG, De Meyer GR.
Differential effect of the protein synthesis inhibitors puromycin and cycloheximide on vascular smooth muscle cell viability.
J Pharmacol Exp Ther. 2008 Jun;325(3):824-32. |
| | Vajda S, Bartha K, Wilhelm I, Krizbai IA, Adam-Vizi V.
Identification of protease-activated receptor-4 (PAR-4) in puromycin-purified brain capillary endothelial cells cultured on Matrigel.
Neurochem Int. 2008 May;52(6):1234-9 |
| | Jo YI, Cheng H, Wang S, Moeckel GW, Harris RC.
Puromycin induces reversible proteinuric injury in transgenic mice expressing cyclooxygenase-2 in podocytes.
Nephron Exp Nephrol. 2007;107(3):e87-94. |
|
|
